Financial Contrast: Epirus Biopharmaceuticals (EPRS) & Its Rivals
Epirus Biopharmaceuticals (NASDAQ: EPRS) is one of 95 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Epirus Biopharmaceuticals to related companies based on the strength of its risk, dividends, earnings, valuation, profitability, analyst recommendations and institutional ownership.
Risk and Volatility
Epirus Biopharmaceuticals has a beta of 2.52, suggesting that its stock price is 152% more volatile than the S&P 500. Comparatively, Epirus Biopharmaceuticals’ peers have a beta of 1.13, suggesting that their average stock price is 13% more volatile than the S&P 500.
Valuation & Earnings
This table compares Epirus Biopharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Epirus Biopharmaceuticals Competitors||$224.58 million||$57.96 million||-1.20|
Epirus Biopharmaceuticals’ peers have higher revenue and earnings than Epirus Biopharmaceuticals. Epirus Biopharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 19.6% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Epirus Biopharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Epirus Biopharmaceuticals Competitors||-910.58%||-183.99%||-27.07%|
This is a summary of recent recommendations for Epirus Biopharmaceuticals and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Epirus Biopharmaceuticals Competitors||123||465||1163||11||2.60|
As a group, “Biotechnology” companies have a potential upside of 58.97%. Given Epirus Biopharmaceuticals’ peers higher probable upside, analysts plainly believe Epirus Biopharmaceuticals has less favorable growth aspects than its peers.
Epirus Biopharmaceuticals peers beat Epirus Biopharmaceuticals on 7 of the 8 factors compared.
About Epirus Biopharmaceuticals
EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company’s products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Receive News & Ratings for Epirus Biopharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epirus Biopharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.